NASDAQ:SMMT Summit Therapeutics (SMMT) Stock Price, News & Analysis $16.75 0.00 (0.00%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$16.80 +0.05 (+0.27%) As of 10/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Summit Therapeutics Stock (NASDAQ:SMMT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Summit Therapeutics alerts:Sign Up Key Stats Today's Range$16.66▼$17.3250-Day Range$12.43▼$18.4252-Week Range$12.07▼$29.23Volume5.19 million shsAverage Volume7.08 million shsMarket Capitalization$13.36 billionP/E RatioN/ADividend YieldN/APrice Target$28.61Consensus RatingModerate Buy Company Overview Summit Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company’s lead program is ivonescimab, an investigational bispecific antibody designed to combine immune checkpoint inhibition targeting PD-1 with anti-angiogenic activity targeting VEGF. Summit is evaluating ivonescimab in clinical studies for multiple solid tumors, including non-small cell lung cancer. Summit obtained exclusive rights from Akeso, Inc. to develop and commercialize ivonescimab in markets outside China, including the United States and other international territories. Akeso retains rights in China and certain related markets. The program is being advanced through clinical development and regulatory activities intended to assess its safety and effectiveness as a potential treatment for patients with cancer. Founded in the United Kingdom, Summit historically worked on therapies for infectious diseases, including the investigational antibiotic ridinilazole for Clostridioides difficile infection, before shifting its strategic focus to oncology. The company is led by Robert W. Duggan, who serves as chairman and chief executive officer. Summit Therapeutics is headquartered in Miami, Florida, and its ordinary shares trade on the Nasdaq under the symbol SMMT.AI Generated. May Contain Errors. Read More Summit Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreSMMT MarketRank™: Summit Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 381st out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingSummit Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 1 strong buy rating, 9 buy ratings, 8 hold ratings, and 1 sell rating.Upside PotentialSummit Therapeutics has a consensus price target of $28.61, representing about 70.8% upside from its current price of $16.75.Amount of Analyst CoverageSummit Therapeutics has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Summit Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Summit Therapeutics are expected to decrease in the coming year, from ($1.20) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Summit Therapeutics is -14.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Summit Therapeutics is -14.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSummit Therapeutics has a P/B Ratio of 19.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Summit Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted31.21% of the float of Summit Therapeutics has been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 6.56.Change versus previous monthShort interest in Summit Therapeutics has recently decreased by 0.60%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSummit Therapeutics does not currently pay a dividend.Dividend GrowthSummit Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.37 News SentimentSummit Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Summit Therapeutics this week, compared to 5 articles on an average week.Search Interest35 people have searched for SMMT on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows11 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Summit Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders83.50% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions4.61% of the stock of Summit Therapeutics is held by institutions.Read more about Summit Therapeutics' insider trading history. Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SMMT Stock News HeadlinesSummit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial CollaborationOctober 2 at 12:07 AM | finance.yahoo.comDaiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus IvonescimabOctober 2 at 2:06 PM | rttnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Summit Therapeutics (NASDAQ:SMMT) Shares Climb 7.1% - Here's What HappenedOctober 2 at 7:21 AM | americanbankingnews.comSummit agrees to $2 billion AstraZeneca equity investmentOctober 2 at 6:02 AM | americanbankingnews.comSummit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC DatrowayOctober 2 at 2:30 AM | businesswire.comDaiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor TypesOctober 2 at 2:30 AM | businesswire.comWhat Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership?October 1, 2026 | finance.yahoo.comSee More Headlines SMMT Stock Analysis - Frequently Asked Questions How have SMMT shares performed this year? Summit Therapeutics' stock was trading at $17.49 on January 1st, 2026. Since then, SMMT shares have decreased by 4.2% and is now trading at $16.75. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics PLC (NASDAQ:SMMT) released its earnings results on Thursday, July, 23rd. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.01. Read the conference call transcript. When did Summit Therapeutics IPO? Summit Therapeutics (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager. Who are Summit Therapeutics' major shareholders? Top institutional shareholders of Summit Therapeutics include CX Institutional. Insiders that own company stock include Mahkam Zanganeh, Robert W Duggan, Yu Xia, Manmeet Singh Soni and Ankur Dhingra. View institutional ownership trends. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings7/23/2026Today10/05/2026Next Earnings (Estimated)10/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SMMT's financial health is in the Yellow zone, according to TradeSmith. SMMT has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SMMT CIK1599298 Webwww.smmttx.com Phone650-460-8308Fax44-12-3544-3999Employees265Year Founded2003Price Target and Rating Average Price Target for Summit Therapeutics$28.61 High Price Target$43.00 Low Price Target$11.90 Potential Upside/Downside+70.8%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.08 billion Net MarginsN/A Pretax MarginN/A Return on Equity-168.94% Return on Assets-141.92% Debt Debt-to-Equity RatioN/A Current Ratio6.96 Quick Ratio6.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book19.71Miscellaneous Outstanding Shares797,750,000Free Float131,629,000Market Cap$13.36 billion OptionableOptionable Beta-1.51 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:SMMT) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
